CL2025003367A1 - Nanosupensiones de corticosteroides y sus usos - Google Patents
Nanosupensiones de corticosteroides y sus usosInfo
- Publication number
- CL2025003367A1 CL2025003367A1 CL2025003367A CL2025003367A CL2025003367A1 CL 2025003367 A1 CL2025003367 A1 CL 2025003367A1 CL 2025003367 A CL2025003367 A CL 2025003367A CL 2025003367 A CL2025003367 A CL 2025003367A CL 2025003367 A1 CL2025003367 A1 CL 2025003367A1
- Authority
- CL
- Chile
- Prior art keywords
- nanosuppressions
- corticosteroid
- treat
- enthesitis
- tenosynovitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202363463113P | 2023-05-01 | 2023-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2025003367A1 true CL2025003367A1 (es) | 2026-03-06 |
Family
ID=93333275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025003367A CL2025003367A1 (es) | 2023-05-01 | 2025-10-30 | Nanosupensiones de corticosteroides y sus usos |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4704852A2 (fr) |
| KR (1) | KR20260005253A (fr) |
| CN (1) | CN121038796A (fr) |
| AU (1) | AU2024265712A1 (fr) |
| CL (1) | CL2025003367A1 (fr) |
| CO (1) | CO2025015291A2 (fr) |
| IL (1) | IL324263A (fr) |
| JO (1) | JOP20250270A1 (fr) |
| MX (1) | MX2025013065A (fr) |
| TW (1) | TW202448423A (fr) |
| WO (1) | WO2024228993A2 (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI773641B (zh) * | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑 |
| HUE055016T2 (hu) * | 2017-06-23 | 2021-10-28 | Salvat Lab Sa | Olaj-a-vízben nanoemulziós klobetazol készítmény |
-
2024
- 2024-04-30 CN CN202480029391.1A patent/CN121038796A/zh active Pending
- 2024-04-30 AU AU2024265712A patent/AU2024265712A1/en active Pending
- 2024-04-30 KR KR1020257036363A patent/KR20260005253A/ko active Pending
- 2024-04-30 WO PCT/US2024/026982 patent/WO2024228993A2/fr not_active Ceased
- 2024-04-30 EP EP24800432.7A patent/EP4704852A2/fr active Pending
- 2024-04-30 TW TW113116200A patent/TW202448423A/zh unknown
-
2025
- 2025-10-27 IL IL324263A patent/IL324263A/en unknown
- 2025-10-29 JO JOJO/P/2025/0270A patent/JOP20250270A1/ar unknown
- 2025-10-30 CL CL2025003367A patent/CL2025003367A1/es unknown
- 2025-10-31 MX MX2025013065A patent/MX2025013065A/es unknown
- 2025-10-31 CO CONC2025/0015291A patent/CO2025015291A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2025015291A2 (es) | 2025-11-19 |
| KR20260005253A (ko) | 2026-01-09 |
| EP4704852A2 (fr) | 2026-03-11 |
| MX2025013065A (es) | 2025-12-01 |
| WO2024228993A2 (fr) | 2024-11-07 |
| JOP20250270A1 (ar) | 2025-10-29 |
| AU2024265712A1 (en) | 2025-11-13 |
| CN121038796A (zh) | 2025-11-28 |
| IL324263A (en) | 2025-12-01 |
| WO2024228993A3 (fr) | 2025-03-20 |
| TW202448423A (zh) | 2024-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002573A1 (es) | Inhibidores atf6 y sus usos. | |
| ECSP22051247A (es) | Fluoroalquil-oxadiazoles y sus usos | |
| AR034619A1 (es) | Formulaciones de olopatadine para administracion topica | |
| MX388437B (es) | Composiciones de cannabidiol y usos de las mismas. | |
| BR112022019794A2 (pt) | Derivados de pirrolo[2,3-f]indazol e 2,4,5,10-tetrazatriciclo[7.3.0.03,7]dodeca-1,3(7),5,8,11- penteno como moduladores da alfa-1-antitripsina para tratamento da deficiência de alfa-1-antitripsina (aatd) | |
| CL2022003348A1 (es) | Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios | |
| UY4906S (es) | Par de audífonos | |
| BR112019001921A2 (pt) | moduladores do receptor nmda de espiro-lactama e seus usos | |
| MX2024010236A (es) | Akkermansia para prevenir y/o tratar trastornos de desregulación de la recompensa. | |
| CO2025015291A2 (es) | Nanosupensiones de corticosteroides y sus usos | |
| MX2024006768A (es) | Compuestos y usos de los mismos. | |
| BR112018077060A2 (pt) | composição antimicrobiana e métodos que empregam a mesma | |
| UY39482A (es) | Compuestos moduladores del cftr, composiciones y usos de estos | |
| CL2020003458S1 (es) | Auriculares. | |
| BR112021019854A2 (pt) | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares | |
| BR112022017193A2 (pt) | Composições para interromper a formação de biofilme e para tratar distúrbios relacionados a biofilme | |
| MX420447B (es) | Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona | |
| BR112012007091A2 (pt) | composições de olopatadina e seus usos | |
| Karkos et al. | Evidence-based applications of mitomycin C in the nose | |
| ECSP22008993A (es) | Derivados de alcohol como abridores del canal de potasio kv7 | |
| EP4090420A4 (fr) | Traitement photothérapeutique d'affections cutanées | |
| CO2023014093A2 (es) | Formulaciones de l-asparaginasa | |
| CO2023003129A2 (es) | Vacunas contra infecciones por sars-cov-2 | |
| MX2024007944A (es) | Derivados de 4-fenil-tetrahidropiridina para el tratamiento de enfermedades auditivas. | |
| CA3135658A1 (en) | Mesenchymal stem cells for treatment of skin disorders and skin problems |